Literature DB >> 14715122

Ovarian follicular development during the use of oral contraception: a review.

Angela R Baerwald1, Roger A Pierson.   

Abstract

Over the past 40 years, alterations to the composition of oral contraceptives (OCs) have been made in attempts to reduce adverse effects and to improve patient compliance while maintaining contraceptive efficacy. However, there is growing evidence to indicate that reducing the estrogen dose to minimize adverse effects may have compromised the degree of hypothalamo-pituitary-ovarian suppression, particularly during the hormone-free interval (HFI) or following missed doses. Follicle development during OC use appears to occur in association with a loss of endocrine suppression during the HFI. This information provides a rationale for reducing or eliminating the HFI in OC regimens. There is also evidence for an increased risk of follicle development and ovulation in women who use delayed OC initiation schemes, such as the "Sunday Start" method. It is not currently known why some follicles ovulate during OC use while others regress or form anovulatory follicle cysts. Continued research about follicle development during OC use would provide insight into understanding the precise mechanisms of action underlying combined OCs, as well as those of continuous OC formulations and emergency contraceptive regimens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715122      PMCID: PMC2891973          DOI: 10.1016/s1701-2163(16)30692-2

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  68 in total

1.  Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.

Authors:  A M van Heusden; B C Fauser
Journal:  Contraception       Date:  1999-04       Impact factor: 3.375

2.  Fertility control with oral medication.

Authors:  G PINCUS; J ROCK; C R GARCIA; E RICEWRAY; M PANIAGUA; I RODRIGUEZ
Journal:  Am J Obstet Gynecol       Date:  1958-06       Impact factor: 8.661

3.  Effect of "missed" pills on oral contraceptive effectiveness.

Authors:  G S Letterie; G E Chow
Journal:  Obstet Gynecol       Date:  1992-06       Impact factor: 7.661

4.  The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth.

Authors:  A T Teichmann; K Brill; M Albring; J Schnitker; P Wojtynek; E Kustra
Journal:  Gynecol Endocrinol       Date:  1995-12       Impact factor: 2.260

5.  Ovarian function during low-dose oral contraceptive use.

Authors:  C Egarter; M Putz; H Strohmer; P Speiser; R Wenzl; J Huber
Journal:  Contraception       Date:  1995-06       Impact factor: 3.375

6.  Enlarged follicles in women using oral contraceptives.

Authors:  M Broome; J Clayton; K Fotherby
Journal:  Contraception       Date:  1995-07       Impact factor: 3.375

7.  Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives.

Authors:  V L Holt; J R Daling; B McKnight; D Moore; A Stergachis; N S Weiss
Journal:  Obstet Gynecol       Date:  1992-04       Impact factor: 7.661

8.  Oral contraceptive type and functional ovarian cysts.

Authors:  S F Lanes; B Birmann; A M Walker; S Singer
Journal:  Am J Obstet Gynecol       Date:  1992-03       Impact factor: 8.661

9.  Early folliculogenesis in primate ovaries: testing the role of estrogen.

Authors:  M J Koering; D R Danforth; G D Hodgen
Journal:  Biol Reprod       Date:  1991-12       Impact factor: 4.285

10.  Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive.

Authors:  R S London; A Chapdelaine; D Upmalis; W Olson; J Smith
Journal:  Acta Obstet Gynecol Scand Suppl       Date:  1992
View more
  5 in total

1.  Evaluation of texture features for analysis of ovarian follicular development.

Authors:  Na Bian; Mark G Eramian; Roger A Pierson
Journal:  Med Image Comput Comput Assist Interv       Date:  2006

Review 2.  Effect of missed combined hormonal contraceptives on contraceptive effectiveness: a systematic review.

Authors:  Lauren B Zapata; Maria W Steenland; Dalia Brahmi; Polly A Marchbanks; Kathryn M Curtis
Journal:  Contraception       Date:  2012-10-22       Impact factor: 3.375

3.  Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.

Authors:  Julia Winkler; Mark Goldammer; Matthias Ludwig; Beate Rohde; Christian Zurth
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-07-06       Impact factor: 2.441

4.  Hormonal Contraception and the Informed Consent.

Authors:  David J Hilger; Kathleen M Raviele; Teresa A Hilgers
Journal:  Linacre Q       Date:  2018-12-04

5.  Nomegestrol acetate-17b-estradiol for oral contraception.

Authors:  Anne Burke
Journal:  Patient Prefer Adherence       Date:  2013-06-27       Impact factor: 2.711

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.